These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 6994788)

  • 1. Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity.
    Schoeppe W; Brecht HM
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6994788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension.
    Manhem P; Hökfelt B
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):109S-114S. PubMed ID: 6994763
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of guanfacine on blood pressure and renin activity in hypertensive patients.
    Rosenthal J
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):91S-96S. PubMed ID: 6994787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
    Collart F; Staroukine M; Verniory A
    Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of long-term treatment of essential hypertension with guanfacine.
    Higuchi M; Overlack A; Stumpe KO
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):61S-64S. PubMed ID: 6994780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension.
    Hauger-Klevene JH; Balossi EC; Scornavacchi JC
    Am J Cardiol; 1986 Mar; 57(9):27E-31E. PubMed ID: 3513527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ambulatory trial of guanfacine.
    Mann S; Millar Craig MW; Melville DI; Cashman PM; Raftery EB
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):103S-107S. PubMed ID: 6994762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of single and multiple doses of guanfacine in essential hypertension.
    Zamboulis C; Reid JL
    Clin Pharmacol Ther; 1980 Dec; 28(6):715-21. PubMed ID: 7002428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of guanfacine monotherapy on blood pressure, heart rate, plasma renin activity, aldosterone, and catecholamines in hypertensive patients with chronic glomerulonephritis.
    Ikeda T; Gomi T; Yuhara M; Sakurai J; Nakayama D
    Clin Pharmacol Ther; 1988 Mar; 43(3):278-82. PubMed ID: 3278821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic renal effects of guanfacine in essential and renal hypertension.
    Roeckel A; Heidland A
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):141S-149S. PubMed ID: 6994769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood pressure and renin under treatment of hypertension with guanfacine (author's transl)].
    Rosenthal J; Jäger H
    MMW Munch Med Wochenschr; 1980 Jan; 122(4):137-40. PubMed ID: 6767938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients.
    Velasco M; Urbina-Quintana A; Morillo J; Vizcarrondo H; Ramirez A; Hernández E; Hernández-Pieretti O
    Eur J Clin Pharmacol; 1984; 27(4):393-6. PubMed ID: 6394347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of long-term treatment with guanfacine on selected humoral metabolic indices in patients with primary hypertension].
    Knypl K; Wocial B; Chodakowska J; Brym E; Czerniewska E; Wacławek-Maczkowska J; Kuczyńska K; Berent H; Januszewicz W
    Pol Tyg Lek; 1989 Mar 20-27; 44(12-13):293-6. PubMed ID: 2530502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanfacine: effects of long-term treatment and withdrawal.
    Reid JL; Zamboulis C; Hamilton CA
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):183S-188S. PubMed ID: 6994774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.
    Rosenthal JH
    Am J Cardiol; 1986 Mar; 57(9):22E-26E. PubMed ID: 3513526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of clonidine and guanfacine in essential hypertension.
    Farsang C; Varga K; Vajda L; Alföldi S; Kapocsi J
    Clin Pharmacol Ther; 1984 Nov; 36(5):588-94. PubMed ID: 6386275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antihypertensive effect of guanfacine in rats].
    Nakagawa Y; Takeda K; Hashimoto T; Sakurai H; Mitomi A; Imai S; Hamamura M; Kumada M
    Nihon Yakurigaku Zasshi; 1981 Mar; 77(3):295-312. PubMed ID: 6762984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamics in hypertensive patients before and during guanfacine treatment.
    Schäfer N; Rauh J; Rosenthal J
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):133S-135S. PubMed ID: 6994767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of prindolol on plasma noradrenaline, plasma renin and sodium-potassium metabolism in patients with essential hypertension.
    Brecht HM; Werner E; Schoeppe W
    Adv Clin Pharmacol; 1976; 11():66-9. PubMed ID: 1032572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of guanfacine after long-term treatment in essential hypertension. Observations on blood pressure and plasma and urinary noradrenaline.
    Zamboulis C; Reid JL
    Eur J Clin Pharmacol; 1981 Jan; 19(1):19-24. PubMed ID: 7007059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.